Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Clinical features and outcomes of 98 children and adults with dense deposit disease.

Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ.

Pediatr Nephrol. 2012 May;27(5):773-81. doi: 10.1007/s00467-011-2059-7. Epub 2011 Nov 22.

2.

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.

Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD.

Clin J Am Soc Nephrol. 2009 Jan;4(1):22-32. doi: 10.2215/CJN.03480708. Epub 2008 Oct 29.

3.

[Clinical and pathological characteristics of children with dense deposit disease].

Liu JC, Yang JY, Xiao HJ, Huang JP, Yao Y, Li X, Wang SX.

Zhonghua Er Ke Za Zhi. 2009 Aug;47(8):593-7. Chinese.

PMID:
19951492
4.

Clinical and pathological features of dense deposit disease in Chinese patients.

Wang J, Tang Z, Luo C, Hu Y, Zeng C, Chen H, Liu Z.

Clin Nephrol. 2012 Sep;78(3):207-15.

PMID:
22874109
5.

Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome.

Andresdottir MB, Assmann KJ, Hoitsma AJ, Koene RA, Wetzels JF.

Nephrol Dial Transplant. 1999 Jul;14(7):1723-31.

PMID:
10435883
6.

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V.

Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63. Epub 2012 Mar 28.

7.

A descriptive study of individuals with membranoproliferative glomerulonephritis.

Lu DF, McCarthy AM, Lanning LD, Delaney C, Porter C.

Nephrol Nurs J. 2007 May-Jun;34(3):295-302; quiz 303.

PMID:
17644874
8.

Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.

Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, Jha V, Sakhuja V, Joshi K.

Diagn Pathol. 2015 Mar 17;10:6. doi: 10.1186/s13000-015-0233-0.

9.

Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease.

Bennett WM, Fassett RG, Walker RG, Fairley KF, d'Apice AJ, Kincaid-Smith P.

Am J Kidney Dis. 1989 Jun;13(6):469-76.

PMID:
2658560
10.

C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT.

Clin J Am Soc Nephrol. 2014 Jan;9(1):46-53. doi: 10.2215/CJN.04700513. Epub 2013 Oct 31.

11.

Long-term clinical and morphological evaluation of primary membranoproliferative glomerulonephritis.

Wu MJ, Shu KH, Chan LP, Lu YS, Cheng CH, Sheu SS, Hsu YH, Lian JD.

Zhonghua Yi Xue Za Zhi (Taipei). 1996 Jan;57(1):34-41.

PMID:
8820034
12.

Dense deposit disease: a 29-years electron microscopy experience.

Seif EI, Ibrahim EA, Elhefnawy NG, Salman MI.

Arab J Nephrol Transplant. 2013 Sep;6(3):153-60.

PMID:
24053741
13.

Eculizumab in dense-deposit disease after renal transplantation.

Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, Rodríguez de Córdoba S, Ybot-González P.

Pediatr Nephrol. 2014 Oct;29(10):2055-9. doi: 10.1007/s00467-014-2839-y. Epub 2014 Jun 8.

PMID:
24908321
14.

Dense deposit disease in Korean children: a multicenter clinicopathologic study.

Park SJ, Kim YJ, Ha TS, Lim BJ, Jeong HJ, Park YH, Lee DY, Kim PK, Kim KS, Chung WY, Shin JI.

J Korean Med Sci. 2012 Oct;27(10):1215-21. doi: 10.3346/jkms.2012.27.10.1215. Epub 2012 Oct 2.

15.

C3 nephritic factor associated with C3 glomerulopathy in children.

Nicolas C, Vuiblet V, Baudouin V, Macher MA, Vrillon I, Biebuyck-Gouge N, Dehennault M, Gié S, Morin D, Nivet H, Nobili F, Ulinski T, Ranchin B, Marinozzi MC, Ngo S, Frémeaux-Bacchi V, Pietrement C.

Pediatr Nephrol. 2014 Jan;29(1):85-94. doi: 10.1007/s00467-013-2605-6. Epub 2013 Sep 26.

PMID:
24068526
16.

Dense deposit disease.

Smith RJ, Harris CL, Pickering MC.

Mol Immunol. 2011 Aug;48(14):1604-10. doi: 10.1016/j.molimm.2011.04.005. Epub 2011 May 24. Review.

17.

Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.

Pediatr Nephrol. 2014 Jun;29(6):1107-11. doi: 10.1007/s00467-013-2711-5. Epub 2014 Jan 10.

PMID:
24408225
18.

Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT.

Pediatr Nephrol. 2014 Jul;29(7):1283-7. doi: 10.1007/s00467-013-2748-5. Epub 2014 Jan 26.

PMID:
24464478
19.

Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.

Ali A, Schlanger L, Nasr SH, Sethi S, Gorbatkin SM.

Am J Kidney Dis. 2016 Mar;67(3):479-82. doi: 10.1053/j.ajkd.2015.10.020. Epub 2015 Dec 17.

PMID:
26704376
20.

C3 glomerulopathy.

Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P.

Contrib Nephrol. 2013;181:185-93. doi: 10.1159/000348654. Epub 2013 May 8. Review.

PMID:
23689580

Supplemental Content

Support Center